TOULOUSE, France & FULLERTON, Calif., January 23, 2026--(BUSINESS WIRE)--Regulatory News:
ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible), a next-generation biopharma company pioneering a new therapeutic era in sepsis and critical care through its proprietary apoA-I–based technology platform, today announces its financial calendar for 2026.
Events | Dates* |
Cash position and activity update for Q4 2025 | Thursday, February 26, 2026 |
2025 Full-Year Results | Thursday, March 12, 2026 |
Cash position and activity update for Q1 2026 | Thursday, May 28, 2026 |
Cash position and activity update for Q2 2026 | Thursday, August 27, 2026 |
2026 Half-Year Results | Thursday, September 24, 2026 |
Cash position and activity update for Q3 2026 | Thursday, November 26, 2026 |
* indicative dates subject to change |
About ABIONYX Pharma
ABIONYX Pharma is a next-generation biopharma company pioneering a new therapeutic era in sepsis and critical care through breakthrough biotherapies that address life-threatening conditions with no effective treatments. Leveraging its proprietary apoA-I–based technology platform, ABIONYX Pharma develops innovative biologics and HDL-derived vectors that target the immune and inflammatory dysregulation underlying sepsis and other severe diseases. With a strong scientific foundation and a growing network of global clinical partners, ABIONYX Pharma aims to redefine the standard of care in sepsis and to bring critical care solutions to patients worldwide.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260123890011/en/
Contacts
ABIONYX Pharma
infos@abionyx.com